The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors. by Ellwood, Philippa et al.
Ellwood, P. ; Asher, M.I. ; Billo, N.E. ; Bissell, K. ; Chiang, C.Y. ;
Ellwood, E.M. ; El-Sony, A. ; Garca-Marcos, L. ; Mallol, J. ; Marks,
G.B. ; Pearce, N.E. ; Strachan, D.P. (2016) [Accepted Manuscript]
The Global Asthma Network rationale and methods for Phase I global
surveillance: prevalence, severity, management and risk factors. The
European respiratory journal. ISSN 0903-1936
Downloaded from: http://researchonline.lshtm.ac.uk/3449881/
DOI:
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
1 
 
The Global Asthma Network (GAN) 
Rationale and Methods for Phase I Global Surveillance: 
Prevalence, Severity, Management and Risk Factors 
 
 
 
 
 
 
Ellwood P1, Asher MI1, Ellwood E1, García-Marcos L2, Pearce N3 and the GAN Steering 
Group* 
 
1 Department of Paediatrics: Child and Youth Health, University of Auckland, Auckland, 
New Zealand 
2 University of Murcia, Pabellon Docente Universitario, Murcia, Spain 
3 London School of Hygiene and Tropical Medicine, London, United Kingdom 
* Steering Group members are listed at the end of the paper 
 
 
 
 
 
 
 
Address for correspondence: 
 
Mrs Philippa Ellwood MPH 
Department of Paediatrics: Child and Youth Health 
University of Auckland 
Private Bag 92019 
Auckland 1010 
New Zealand 
Tel:  +64 9 9236451 
Fax:  +64 9 373 7602 
Email:  p.ellwood@auckland.ac.nz 
 
 
 
 
 
Running title:  GAN Phase I Methods 
 
 
Key words: asthma, allergic rhinitis, eczema, adults, children, epidemiology, Global 
Asthma Network 
 
 
Word count 3075  
2 
 
ABSTRACT 
The Global Asthma Network (GAN) was established commenced in 2012 to improve asthma 
care globally, with a focus on low- and middle-income countries, through enhanced 
surveillance, research collaboration, capacity building and access to quality-assured essential 
medicines. The Network was established following on from the long-term programme of 
work of the International Study of Asthma and Allergies in Childhood (ISAAC). GAN Phase 
I represents a continuation and development of the global asthma surveillance and research 
conducted under ISAAC, particularly ISAAC Phase One and ISAAC Phase Three. and the 
publication of the Global Asthma Report 2011 with the International Union against 
Tuberculosis and Lung Disease (The Union).  
The Global Asthma Network will build on the findings from ISAAC, by collecting further 
information on asthma, rhinitis and eczema prevalence and severity, diagnoses, asthma 
emergency room visits and hospital admissions, management policies and access to quality 
assured essential medicines. As with the ISAAC study, GAN Phase I will is the first major 
global surveillance of asthma prevalence, severity, management and risk factors which 
includes two age groups of school children (6-7 and 13-14 year olds); it also includes, for the 
first time, and also adults/parents of each age group. ItThis will also include centres in “new” 
countries to provide new information about changes in risk factors to increase the current 
understanding of these conditions and monitor time trends. GAN will continue to promote the 
recognition of asthma as an important non-communicable disease to increase understanding 
and reduce worldwide suffering. 
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BACKGROUND 
The Global Asthma Network (GAN) was established in 2012, 2012 to improve asthma care 
globally, with a focus on low- and middle-income countries, through enhanced surveillance, 
research collaboration, capacity building and access to quality-assured essential medicines. 
The Network was established following on from the 21 year programme of work (1991-2012) 
of the International Study of Asthma and Allergies (ISAAC) and the International Union 
Against Tuberculosis and Lung Disease (The Union). GAN is a new and independent 
organisation, but the GAN Steering Group is made up of several members from ISAAC and 
The Union. 
 
These two organisations have been dedicated to helping countries worldwide identify and 
address the growing global problem of asthma which has established itself as an important 
Non-communicable Disease (NCD) globally. In 2011, the Union andapproached ISAAC to 
prepared The Global Asthma Report 2011 which was launched in New York on 19th 
September 2011 coinciding with the United Nations High-Level meeting on NCDs in New 
York, 19-20 September 2011. Subsequently GAN produced The Global Asthma Report 2014 
which was launched at the 45th Union World Conference on Lung Health, Barcelona, Spain, 
28 October to 1 November 2014. The GAN Steering Group is made up of some members 
from each of the founding organisations, ISAAC and The Union. 
 
GAN aims to progress recommendations in the reports and engage Government’s health 
ministers, policy-makers, health workers, those living with asthma, development partners, 
donors and media in efforts to improve asthma care globally. Core activities of GAN are: 
global surveillance; promotion and backing of standard case management of asthma; 
operational research; capacity building; engagement with policy makers; and access to 
affordable quality-assured medicines. 
 
 
RATIONALE FOR GAN 
GAN Phase I represents a continuation and development of the global asthma surveillance 
and research conducted under ISAAC, particularly GAN will also build on the global 
findings from ISAAC Phases One1-5 Two6 [There is not one main overview paper-there are 
around 12 Phase 2 papers should they all be referenced here?]  and Three7-9, the Phase Three 
time trends papers10-13 and from the environmental questionnaire[what refs here?- all of 
them?or website publications address] . 
 
ISAAC Phase One14 (1994-1995), involveding over 700,000 children of two age groups 
(13/14 and 6/7 year olds) from 156 centres in 56 countries. It identified large variations in the 
prevalence of symptoms of asthma, rhinitis and eczema throughout the world with 
differences of between 20 fold and 60 fold between centres. Phase One also showed that the 
international patterns of disease prevalence could not be explained by the current 
understanding, at the time, of the aetiology of asthma rhinitis and eczema. A consistent 
finding in Phase One was the marked differences in asthma prevalence in populations with 
similar genetic or ethnic backgrounds15, suggesting that environmental factors in the broadest 
sense were the major determinants of the prevalence of asthma in a community. Ecological 
analyses using Phase One data found no associations with pollen16, immunisations17, 
tobacco18, climate19 or antibiotics20. However negative associations were found with 
tuberculosis21, 22 and higher dietary plant intake23, and positive associations were found with 
economic development24 and dietary trans fatty acids25 suggesting those findings were 
worthy to be investigated in more depth. 
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ISAAC Phase Two26 began in 1998 and was undertaken in 30 centres from 22 countries 
involving 53,383 children aged between 10 and 12 using child contact modules.  This age 
group was chosen as they were more likely to understand the procedures than 6-7 year olds 
and to be more compliant that 13-14 year olds. Comparisons between populations (centres) 
were undertaken using objective measures of disease, and assessment of environment, 
lifestyle, and clinical management. Populations which were potentially informative were 
involved, such as those with contrasting prevalence of disease, environmental exposures, 
management or genetic factors. ISAAC Phase Two enabled the description of variation in 
disease prevalence beyond the level measured in Phase One by core questionnaires. Markers 
of disease were related to individual exposure to environmental factors and genetic markers. 
ISAAC Phase Two showed little evidence of genetic factors in asthma and that most asthma, 
rhinitis and eczema has a non-allergic basis, especially in developing countries. 
 
ISAAC Phase Three27 fieldwork was undertaken between 2001 and 2003. It involved over 
xxx,000 children of two age groups (13/14 and 6/7 year olds) from xxx centres in xx 
countries. The methodology involved and was a repeat of the Phase One core questions, using 
the same age groups, with the addition of an environmental questionnaire to explore in more 
depth the findings from the Phase One ecological analyses and other potential risk factors. 
Initially, Phase Three was designed to assesso look at time trends in centres that had 
alsoparticipated in Phase One; however,, but new centres were encouraged to participate to 
obtain a more comprehensive global map of the three conditions particularly in low and 
middle income countries. ISAAC Phase Three has been a crucial part of the process by which 
the extent, nature and causes of the global increases in the prevalence of these conditions are 
understood, particularly from the findings of the environmental data. Areas of interest 
include: paracetamol and antibiotic use particularly in the first year of life; breastfeeding; 
frequency of truck traffic in the street of residence; association with farm animals in 
pregnancy; exposure to cats and dogs in the first year of life; air pollution; tobacco use, body 
mass index; diet; use of cooking fuels, birthweight; migration; and siblings. 
 
GOALS of GAN: 
(i) Global surveillance. Conduct asthma surveillance around the world and produce and 
disseminate surveillance data to achieve global recognition of the burden of asthma, 
especially the burden in low- and middle-income countries. 
(ii) Management.  Promote effective, efficient, appropriate, affordable and accessible 
asthma management and care to reduce the rates of death, disability and suffering 
caused by asthma. 
(iii) Research. Research, develop and share evidence, success stories and practical tools 
that enable countries to improve and expand asthma management and prevention 
activities, organise the care of asthma patients to cover their whole populations. 
(iv) Capacity-building. Stimulate capacity-building in surveillance, health education and 
asthma standard case management and research in asthma, especially in low- and 
middle-income countries. 
(v)  Access to affordable quality-assured essential medicines. Ensure quality-assured 
essential asthma medicines are available and affordable in all countries - promotes a 
quality improvement package for the diagnosis, treatment and management of asthma.  
(vi) Communication and advocacy on asthma and chronic airflow limitation. Raise 
the profile of asthma and chronic airflow limitation on national multilateral and global 
agendas and empower other organisations to do the same. 
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RESEARCH DESIGN AND METHODS 
Overview of the GAN Phase I study design 
GAN Phase I is a cross-sectional, multi-centre, multi-country, epidemiological research 
methodology which will follow and expand on the ISAAC Phase Three methodology. In 
particular, it will to include additionalmore in-depth questions on the environment risk 
factors, and on and management of asthma. The  manual containing the information required 
to undertake the fieldwork is available from the GAN website 
http://www.globalasthmanetwork.org/surveillance/manual/manual.php. Each centre has a 
defined geographical area and the centres that undertook ISAAC Phase Three and/or Phase 
One are expected to use the same sampling frame so that comparisons of data can be 
subsequently undertaken. Principal Investigators are identified at the registration stage which 
began in November 2015. The Phase I Co-ordinator is Professor Neil Pearce, London School 
of Hygiene & Tropical Medicine, London, UK who will lead the main data centre. Professor 
Luis Garcia-Marcos, IMIB Research Institute and University of Murcia, Spain will lead the 
data centre for Spanish and Portuguese language centres. The GAN Global Centre, will be led 
by Professor Innes Asher, the University of Auckland, Auckland, New Zealand, assisted by 
Philippa Ellwood as research manager. 
 
Classification of GAN Phase I Centres 
Centres that participated in ISAAC Phase Three have been encouraged to participate in GAN, 
however, as in ISAAC, new centres are encouraged to join to obtain wider global 
participation. 
Expression of Interest and Registration forms 
These forms are available from the GAN website. Formal registrations opened in November 
2015. As of 1 December 2015 there have been expressions of interest from 338 centres in 131 
countries, including and we have received formal registrations from 63 centres in 23 
countries. The Registration form identifies the Principal Investigators (up to two can be 
appointed per centre) and a National Coordinator appointed if there is more than one1 centre 
in a country and if there is an identified need. 
 
Subjects and Selection 
School children 
The same age groups used in ISAAC Phases One and Three will be used in GAN: 13/14 year 
olds (self-completed questionnaires) and 6/7 year olds (parental completed questionnaires). 
The sampling unit will be a school for each age group which will be selected using a table of 
random numbers. A minimum of 10 schools will be required, or all schools in the sampling 
frame if there are fewer than 10 schools. School children are the most accessible people of 
any age group and the 13/14 year age group, the compulsory age group, was chosen to reflect 
the period when mortality from asthma was thought to be more common. It is recommended 
that centres also include the 6/7 year age group which was chosen to give a reflection of the 
early childhood years when asthma is common and admission rates are particularly high. In 
addition, children in many countries do not start school until the age of 6. Students of both 
age groups are selected either by grade/level/year or by age group. 
Adults 
In addition to the 13/14 and 6/7 year age groups, GAN is recommending that the 
adults/parents of both age groups are also surveyedincluded in order to obtain more in-depth 
environmental data, particularly from the parents of the 13/14 year age group that may not 
have been able to answer some questions relating to early life. 
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GAN Phase I Questionnaires 
Demographic questions 
The front page of the questionnaire will collect data on the participant’s name, age, birth date, 
school, gender, and date of interview, although it is acknowledged that some centres will not 
include participants names. Questionnaires will be coded using a unique number for each 
centre, school and participant to ensure anonymity. Collection of data regarding participants 
ethnicity is optional and ethnicity categories from local census forms should be used. 
 
Written questionnaires 
The same standardised core questionnaires developed for ISAAC for use in Phases One and 
Three will be used in GAN with the addition of a question about Doctor diagnosed asthma, 
rhinitis and eczema. The core questions are both sensitive and specific, have good content, 
construct and concurrent and predictive validity28. Height and weight measurements will be 
taken by the fieldworkers. The environmental questionnaire, developed for ISAAC Phase 
Three has been expanded for use in GAN. Not all of these questions are compulsory as 
indicated in the GAN Manual. Some questions that were not considered appropriate for the 
13/14 year age group to complete in ISAAC Phase Three have been included in the Adult 
questionnaire. 
 
Video Asthma Questionnaire 
The international version of the ISAAC video questionnaire used in Phase Three is strongly 
recommended for use in GAN. This 6 minute video shows clinical signs of asthma symptoms 
and was developed by the Wellington Asthma Research Group,  to avoid problems of 
translation and comprehension of terms such as ‘wheeze’ or ‘whistling’ and their use in 
culturally heterogeneous populations29. The video has the advantage of obtaining data from a 
large number of students quickly and efficiently. 
 
Translation of written questionnaires 
The English language version of the questionnaire will be translated to the local language 
using guidelines that were developed in ISAAC Phase One30. Translations are required to 
have the same structure and logic as the English language questionnaire, back translated into 
English by an independent translator and a copy sent to the GAN global centre in Auckland, 
New Zealand. 
 
Sample Size and Power Considerations 
A sample size of 3000 participants per age group (therefore 3000 adults of each group) will 
be used, as in ISAAC. The sample size required to detect differences in severity of asthma is 
higher than that required to detect the same magnitude of differences in the prevalence of 
asthma because severe asthma is less common. The sample size estimates are stringent 
because of the number of hypotheses being tested and the need to be certain of the results in 
such a major study. The sample size enables detection of differences in prevalence of 
wheezing of 30% in one centre and 25% in another centre, with a study power to detect this 
difference of 99% at the 1% level of significance. If the true on-year prevalence of severe 
asthma is 5% in one centre and 3% in another centre with a sample size of 3000, the study 
power to detect this difference with by 90% at the 1% level of significance28. As sampling is 
done by school, while the information is gained from the school pupils, there is likely to be a 
cluster effect. The sample sizes above are sufficiently large to allow good power in the 
presence of moderate intro-cluster correlations. If centres are unable to obtain 3000 
participants, provided they have no less than 1000 and fulfil the criteria described in the GAN 
manual, they may be included. 
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Non-participation 
The mean participation in ISAAC Phase One was 91% for adolescents and 87% for children; 
the corresponding rates for Phase Three were xx% and xx% respectively. A similarly high 
participation is sought for GAN Phase I (at least 80% for 13/14 year olds and 70% for 6/7 
year olds and 70% for adults/parents) due to concerns that pupils may be absent because of 
asthma or allergies.  Marginally lower participation rates may be accepted on a centre by 
centre basis as long as they fulfil the criteria described in the GAN manual. For the 13/14 
year age group a return visit to school can be made to capture the absentees and for the 6/7 
year age group redistribution of questionnaires to the parents can be done once and maybe 
twice.  
 
Quality control 
On lineOn-line documents are now available from the GAN website. The expression of 
interest form has been available since 2012. This has enabled a data base of interested centres 
to be developed and information circulated such as a regular newsletter. The registration 
document became available from November 2015, which is a formal application to 
participate in the GAN Phase One Fieldwork. This form identifies which age groups will be 
studied, the name of the Principal Investigator [PI] (two can be appointed), contact details of 
the PIs, contact person if not the PI. The manual contains all the necessary information 
needed to undertake the fieldwork and describes the criteria required for inclusion in the 
worldwide data set. 
Footnotes 
On completion of the data checks and methodology checks from the centre report any 
deviations from protocol will be examined carefully by the GAN Steering Group. Provided 
the deviation from protocol is not severe enough for exclusion of the centre, the data will be 
included in the analyses and subsequent publications. Protocol variations that are accepted 
will be footnoted in the tables of the publications. This follows the same principles as adopted 
in ISAAC Phases One and Three. 
 
Centre Report 
Once registrated centres are emailed a personal copy of the centre report for use during 
fieldwork. This centre report will be available to be completed on lineon-line shortly so that 
the information can be completed directly on lineon-line and submitted via the website to the 
GAN Global centre in Auckland, New Zealand. 
 
 
Data Handling 
At the time of conducting the survey, fieldworkers are requested to check the questionnaires 
for any obvious demographic entry errors so that this information can be corrected using 
school records. No alteration to the symptom and environmental questionnaire data is 
allowed. Data is entered onto the computer as it is presented on the questionnaire, preserving 
anonymity by coding. At least 10% of the data must be double entered so as to identify data 
entry errors. Each centre is responsible for its own data coding and entry. An epi info package 
will be made available on the GAN website for investigators use. Some centres may wish to 
use questionnaire scanning software such as OMR (Optical Mark Recognition) for data entry, 
however procedures to deal with data entry errors must be documented and sent to the GAN 
Global Centre. The software should have the ability to export the data set as a .CSV file. 
 
 
Data Centres 
Data will be submitted to the GAN Global Centre, Auckland, New Zealand, at the same time 
the centre report is submitted. The GAN Global Centre will acknowledge receipt of the data 
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and centre report, will undertake some quality control checks and will then send the data to 
one of two designated data centres. 
Murcia, Spain. The data centre in Murcia, led by Professor Luis Garcia-Marcos will 
undertake the data checks on all Spanish and Portuguese speaking centres. 
London, United Kingdom. The data centre in London, led by Professor Neil Pearce will 
undertake the data checks for centres using all other languages. 
 
 
Ownership of data, ethics, dissemination of results and funding 
Each centre owns its own data and is free to publish this data without prior approval of the 
GAN Steering Group (however the GAN Data Centres would appreciate being sent copies of 
any publications so that these can be uploaded to the GAN website). All worldwide 
publications will have a writing group ‘and the Global Asthma Network Phase 1 Study 
Group’. This group, comprising all Steering Group members, National Coordinators (if one 
has been appointed) and Principal Investigators will be named at the end of each paper. They 
will be consulted on the paper in preparation prior to journal submission. Each centre is 
required to obtain ethics approval from their local ethics committee prior to the start of their 
study. Each centre is required to provide their own funding. 
 
Significance of GAN 
This will be the first major global surveillance of asthma prevalence, severity, management 
and risk factors which includes adults/parents in addition to two age groups of school 
children and the adults/parents of each age group. GAN will also It is anticipated that a large 
number of centres will adhere to the GAN fieldwork protocol to collect further information 
on the topics addressed in the Global Asthma Reports 2011 and 2014: including asthma 
prevalence and severity; diagnosis of asthma; unplanned visits including emergency room 
visits and hospital admissions; management policies; and access to quality assured essential 
medicines. In addition, GAN will expand on the ISAAC time trends Phase Three findings to 
explore in depth the negative and positive associations found with the environmental data. 
New centres from countries that had not previously undertaken ISAAC will provide rich new 
information and the data from centres that previously have undertaken ISAAC will allow 
trends to be analysed. 
 
CONCLUSION 
ISAAC Phase One involved over 700,000 children of two age groups (13/14 and 6/7 year 
olds) from 156 centres in 56 countries; it found marked variation in the prevalence of 
symptoms of asthma, rhinitis and eczema throughout the world which had not been explained 
by the current understanding at the time of these diseases. ISAAC Phase Three involved 
xxx,xxx children in xxx centres in xx countries; it found that the prevalence of asthma was 
increasing in many locations especially in low- and middle- income countries and identified 
several environmental factors that require further investigation. GAN Phase I will provide 
important further information with regards to both asthma surveillance (geographical patterns 
and time trends), and asthma risk factors. The findings from ISAAC have showed little 
evidence of genetic factors in asthma and that most asthma rhinitis and eczema has a non-
allergic basis. ISAAC has also identified environmental factors that may have an important 
impact on the increasing prevalence and severity of these conditions in children and which 
need further exploration. By including the adults/parents of these two age groups of children 
we will provide new information about these conditions. We will work together as a team to 
increase the worldwide understanding of asthma, rhinitis and eczema, reduce suffering of 
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these conditions and continue to promote the recognition of asthma as an important non-
communicable disease. 
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